Press Releases
June, 2026
Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society’s 68th Annual Scientific Meeting
Read MoreNovember, 2025
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
Read MoreJune, 2025
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society’s 67th Annual Scientific Meeting
Read MoreApril, 2025
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Read MoreNovember, 2024
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
Read MoreOctober, 2024
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
Read MoreOctober, 2024
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
Read MoreJune, 2024
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 66th Annual Scientific Meeting
Read MoreJune, 2023
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Read MoreApril, 2023
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
Read MoreMarch, 2023
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
Read MoreFebruary, 2023
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
Read MoreDecember, 2022
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Read MoreNovember, 2022
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Read MoreNovember, 2022
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of Migraine
Read MoreNovember, 2022
Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Read MoreSeptember, 2022
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Read MoreSeptember, 2022
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
Read MoreAugust, 2022
Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Read MoreAugust, 2022
Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program
Read MoreJune, 2022
Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS10
Read MoreJune, 2022
Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific Meeting
Read MoreMay, 2022
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
Read MoreMay, 2022
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Read MoreMarch, 2022
Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting
Read MoreMarch, 2022
Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights
Read MoreFebruary, 2022
Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
Read MoreNovember, 2021
Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Read MoreOctober, 2021
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
Read MoreSeptember, 2021
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read MoreSeptember, 2021
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
Read MoreAugust, 2021
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Read MoreJuly, 2021
Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Read MoreJune, 2021
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
Read MoreMay, 2021
Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights
Read MoreMarch, 2021
Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference
Read MoreMarch, 2021
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Read MoreNovember, 2020
Satsuma Pharmaceuticals to participate in the following November Virtual Investor Conferences
Read MoreNovember, 2020
Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
Read MoreNovember, 2020
Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results
Read MoreSeptember, 2020
Satsuma Pharmaceuticals to Participate in September Virtual Investor Conferences
Read MoreSeptember, 2020
Satsuma Pharmaceuticals Announces Topline Results from EMERGE Phase 3 Trial of STS101 for the Acute Treatment of Migraine
Read MoreAugust, 2020
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101
Read MoreAugust, 2020
Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Read MoreJuly, 2020
Satsuma Pharmaceuticals Announces the Appointment of Thomas M. Soloway to its Board of Directors
Read MoreJune, 2020
Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101 for Acute Treatment of Migraine
Read MoreJune, 2020
Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting hosted via a Virtual Meeting Platform
Read MoreMay, 2020
Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform
Read MoreMay, 2020
Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference
Read MoreApril, 2020
Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine
Read MoreMarch, 2020
Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results
Read MoreFebruary, 2020
Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Read MoreJanuary, 2020
Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain
Read MoreNovember, 2019
Satsuma Pharmaceuticals Reports Third Quarter 2019 Financial and Business Results
Read MoreNovember, 2019
Satsuma Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference
Read MoreSeptember, 2019
Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
Read MoreSeptember, 2019
Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress
Read MoreSeptember, 2019
Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
Read MoreAugust, 2019
Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Read MoreJuly, 2019
Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society’s Annual Scientific Meeting
Read MoreApril, 2019
Satsuma Pharmaceuticals to Present at Needham & Company 18th Annual Healthcare Conference
Read MoreApril, 2019
Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing
Read MoreFebruary, 2019
Satsuma Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
Read MoreFebruary, 2019
Satsuma Pharmaceuticals Provides Corporate Update and Prepares to Advance Lead Product Candidate, STS101, Into Phase 3 Efficacy Trial for Acute Migraine
Read MoreJanuary, 2017